Skip to main content

Tecartus News

Could CAR-T Therapy Be a Cure for Lupus? Early Trials Show Promise

FRIDAY, Aug. 8, 2025 — Systemic lupus erythematosus (SLE) is a complex autoimmune disease with a spectrum of very different manifestations and variable severity. This makes the condition difficult to ...

FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor CAR T Cell Immunotherapies

June 27, 2025 – The U.S. Food and Drug Administration announced today that it has eliminated the Risk Evaluation and Mitigation Strategies (REMS) for currently approved BCMA- and CD19-directed...

Ready-Made Immune Therapy Effective Against Leukemia

MONDAY, April 28, 2025 – A ready-made version of a cutting-edge cancer immunotherapy can effectively defeat blood cancers, a new study says. Researchers have prepared an off-the-shelf version of CAR...

Cutting-Edge Cancer Treatment, CAR T-Cell Therapy, Isn't Known By Most Americans

MONDAY, April 21, 2025 – Chris Vogelsang has had a long and terrible fight with cancer. Fourteen years ago, the 70-year-old man was first diagnosed with an aggressive form of lymphoma. His cancer...

CAR-T Therapy Won't Raise Odds for a Second Cancer, Study Finds

WEDNESDAY, Sept. 11, 2024 – Contrary to a warning placed on labels for CART-T cancer therapies, use of these treatments does not appear to boost the odds for a secondary cancer later, a new study...

FDA Medwatch Alert: Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies Modified to Minimize Burden on Healthcare Delivery System

June 26, 2024 – Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies Modified to Minimize Burden on Healthcare Delivery System A...

FDA Medwatch Alert: FDA Requires Boxed Warning for T Cell Malignancies Following Treatment with BCMA-Directed or CD19-Directed Autologous CAR T Cell Immunotherapies

April 18, 2024 – In November 2023, the Food and Drug Administration (FDA) posted a safety communication to provide information about reports of T cell malignancies including chimeric antigen...

FDA Medwatch Alert: FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies

November 28, 2023 – The Food and Drug Administration (FDA) has received reports of T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment...

U.S. FDA Approves Kite’s Tecartus as the First and Only CAR-T for Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

SANTA MONICA, Calif.--(BUSINESS WIRE) October 01, 2021 – Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has granted approval for Tecartus® ...

FDA Approves Tecartus (brexucabtagene autoleucel) as the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma

SANTA MONICA, Calif.--(BUSINESS WIRE)--Jul. 24, 2020-- Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Tec...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Acute Lymphoblastic Leukemia, Mantle Cell Lymphoma

Tecartus patient information at Drugs.com